FRONTIER II: One Year Outcomes of the New Vascular Closure Device

Original Title: 12-month results of a novel large access closure device: insights from the FRONTIER II Study.
Presenter: Arne Schwindt

 

The FRONTIER II trial assessed the safety and efficacy of the vessel closure device VIVASURE in more than 50 patients using the femoral access for TAVI or aortic endoprosthesis.

Puncture site was assessed at discharge, 30 days, 90 days and one year post procedure. Primary safety end point was complications incidence directly related to the device.

In 58 patients (66 access closure) there were no significant device-related vascular complications. Technical success was 97% and one year follow up in 42 patients did not show major or minor device-related complications

 

Conclusion
The new vessel closure device VIVASURE offers a safe and reliable alternative to the percutaneous closure of a big orifice in the femoral artery.

 

frontier

More articles by this author

VELETI II: PCI to Intermediate coronary SVG lesions with DES

Original Title: Sealing intermediate non-obstructive coronary SVG lesions with DES as a new approach to maintaining vein graft patency and reducing cardiac events: the...

TR-PCI: Upper Extremity Function Post Transradial PCI

Original Title: Upper extremity function post-transradial (TR)-PCI: interim results. Presenter: Eva Zwaan.   The use of transradial access has increased in the clinical practice thanks to the...

TriGuard: NeuroProtection Device during TAVI

Original Title: A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement. Presenter: Alexandra Lansky   This...

MATRIX: Transradial vs. Femoral Access in Non-ST Elevation AMI

Original Title: Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Presenter: Bernardo Cortese.   The MATRIX study showed that the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...